In the past years, the correlation between TP53 and MDS outcome has been studied in more detail, paying special attention to the type of TP53 alterations (mutations vs deletions), to characterize the impact of the TP53 mutations burden and the more complex TP53 allelic state. The gene discussed is TP53; the disease is myelodysplastic syndrome.